Life Sciences

The United States must stand up for innovation in the debate over the U.S.-Mexico-Canada Agreement (USMCA), ITIF's Stephen Ezell, the Macdonald-Laurier Institute's Richard Owens, and Fundacion Idea's Alberto Saracho write in The Hill.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
June 20, 2019
There is an increasingly intense focus in Washington on reducing the price of drugs to bring down health care costs.
June 6, 2019
The United States must stand up for innovation in the debate over the U.S.-Mexico-Canada Agreement (USMCA), ITIF's Stephen Ezell, the Macdonald-Laurier Institute's Richard Owens, and Fundacion Idea's Alberto Saracho write in The Hill.
May 16, 2019
In testimony before the House Oversight Committee, Stephen Ezell explained why the United States leads the world in life-sciences innovation; how the public and private sectors contribute; why innovation depends on the ability to generate revenues; the consequences of price controls; and how best to control health-care costs.
April 22, 2019
Debates over drug pricing often consider the impacts on health and innovation, but rarely examine the costs those drugs offset. According to new research examining drug releases for 67 diseases across 15 countries in the three decades from 1982 to 2015, these offsets are dramatic.
April 15, 2019
Seven case studies showcase how IP rights are enabling innovators in Latin America to help solve some of the greatest global health challenges.
April 9, 2019
America’s ability to compete globally in biomedical innovation is being threatened.
March 25, 2019
NIH funding is critical to improving health outcomes and reducing the societal costs of illnesses. Congress should increase the NIH budget and then maintain regular, steady increases.
March 7, 2019
America’s ascendance as the world’s leader in life-sciences innovation has been the result of thoughtful, intentional public policies, including robust funding for the National Institutes of Health
March 4, 2019
Misusing the “march-in right” provision of the Bayh-Dole Act could negatively impact U.S. life-sciences innovation and result in fewer new drugs.
February 25, 2019
A new study has sought to quantify this impact, tracking the availability of drugs released after 1981 that are designed to treat 66 diseases across 27 countries.

Pages